{"data":{"id":"us/21-cfr-343.22","jurisdiction":"us","citation":"21 CFR 343.22","heading":"Permitted combinations of active ingredients for cardiovascular-rheumatologic use.","body":"Combinations containing aspirin must meet the standards of an acceptable dissolution test, as set forth in § 343.90. The following combinations are permitted: Aspirin identified in §§ 343.12 and 343.13 may be combined with any antacid ingredient identified in § 331.11 of this chapter or any combination of antacids permitted in accordance with § 331.10(a) of this chapter provided that the finished product meets the requirements of § 331.10 of this chapter and is marketed in a form intended for ingestion as a solution.","path":["Title 21—Food and Drugs","CHAPTER I—FOOD AND DRUG ADMINISTRATION, DEPARTMENT OF HEALTH AND HUMAN SERVICES","SUBCHAPTER D—DRUGS FOR HUMAN USE","PART 343—INTERNAL ANALGESIC, ANTIPYRETIC, AND ANTIRHEUMATIC DRUG PRODUCTS FOR OVER-THE-COUNTER HUMAN USE","Subpart B—Active Ingredients"],"source_url":"https://www.ecfr.gov/api/versioner/v1/full/2026-08-25/title-21.xml","current_through":"2026-08-25","vintage":"","retrieved_at":"2026-08-27T02:24:47Z","sha256":"1b89023c0883638582834e9b32af1d43f2920bc18f931a08a5a48df7baf03470","source_id":"us-cfr","stale":true,"prev":"us/21-cfr-343.20","next":"us/21-cfr-343.50-343.60"},"notice":"GroundRules: Original legal text. Not legal advice."}